Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
94.35
-0.40 (-0.42%)
Dec 23, 2024, 3:00 PM EST
Sanofi Revenue
Sanofi had revenue of 14.16B EUR in the quarter ending September 30, 2024, with 11.49% growth. This brings the company's revenue in the last twelve months to 48.45B, up 6.01% year-over-year. In the year 2023, Sanofi had annual revenue of 46.03B with 1.42% growth.
Revenue (ttm)
48.45B EUR
Revenue Growth
+6.01%
P/S Ratio
n/a
Revenue / Employee
562.74K EUR
Employees
86,088
Market Cap
119.50B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.03B | 644.00M | 1.42% |
Dec 31, 2022 | 45.39B | 6.21B | 15.86% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Sanofi News
- 1 day ago - Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines - GlobeNewsWire
- 2 days ago - Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? - Benzinga
- 4 days ago - Sanofi to buy China rights to Cytokinetics lead asset - Seeking Alpha
- 4 days ago - Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China - GuruFocus
- 5 days ago - Presse release: Jean-Paul Kress to join Sanofi's Board of Directors - GlobeNewsWire
- 6 days ago - Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases - Benzinga
- 6 days ago - Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study - GuruFocus
- 7 days ago - Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's - Investopedia